/RVMD
RVMD Stock - Revolution Medicines, Inc.
Healthcare|BiotechnologyNASDAQ
$78.78+3.71%
+$2.82 (+3.71%) • Dec 19
69
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.HOLD
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.100
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).52
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.82
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+0.9%upside
Target: $79.49
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for RVMD
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$77.99 – $79.57
TARGET (TP)$79.50
STOP LOSS$72.48
RISK/REWARD1:0.1
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta0.96
52W High$81.49
52W Low$29.17
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | N/A | $11.58M | $35.38M | $29.39M | $42.98M |
| Gross Profit | $-592,225,000 | $-399,664,000 | $-217,693,000 | $-157,558,000 | $-89,269,000 |
| Gross Margin | N/A | -3451.3% | -615.3% | -536.1% | -207.7% |
| Operating Income | $-689,524,000 | $-487,185,000 | $-258,279,000 | $-188,008,000 | $-110,697,000 |
| Net Income | $-600,093,000 | $-436,367,000 | $-248,705,000 | $-187,091,000 | $-108,159,000 |
| Net Margin | N/A | -3768.3% | -703.0% | -636.6% | -251.6% |
| EPS | $-3.58 | $-3.86 | $-3.08 | $-2.47 | $-1.62 |
Company Overview
Revolution Medicines, Inc., a clinical-stage precision oncology company, focuses on developing therapies to inhibit frontier targets in RAS-addicted cancers. The company is developing RMC-4630, an inhibitor of SHP2, which is in Phase 1/2 clinical trial for the treatment of solid tumors, such as gynecologic and colorectal cancer tumors. It also develops RMC-5845, a selective inhibitor of SOS1, a protein that converts RAS (OFF) to RAS (ON) in cells; and RMC-5552, a hyperactivated selective inhibitor of mTORC1 signaling in tumors. In addition, the company is developing RMC-6291, a mutant-selective inhibitor of KRASG12C(ON) and NRASG12C(ON); and RMC-6236, a RAS-selective inhibitor of multiple RAS(ON) variants. Further, it develops RAS(ON) Inhibitors targeting KRASG13C(ON) and KRASG12D(ON). The company has a collaboration agreement with Sanofi for the research and development of SHP2 inhibitors, including RMC-4630. Revolution Medicines, Inc. was incorporated in 2014 and is headquartered in Redwood City, California.
Visit WebsiteRating Distribution
Strong Buy
2
12%
Buy / Outperform
14
82%
Hold / Neutral
1
6%
Sell / Underperform
0%
Analyst Consensus🟢 Bullish
16 Bullish1 Neutral/Bearish
Price Targets
$57
Average Target
↓ 28.1% Downside
Now
$24
Low
$57
Average
$99
High
Based on 22 analysts
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| November 18th 2025 | Wolfe Research | Initiation | Outperform | $75 |
| November 3rd 2025 | RBC Capital Mkts | Initiation | Outperform | $77 |
| October 21st 2025 | Mizuho | Initiation | Outperform | $90 |
| October 16th 2025 | Stifel | Resumed | Buy | $85 |
| September 12th 2025 | Raymond James | Resumed | Strong Buy | $72 |
| September 5th 2025 | Truist | Initiation | Buy | $99 |
| August 19th 2025 | Piper Sandler | Initiation | Overweight | $75 |
| August 15th 2025 | Wells Fargo | Initiation | Overweight | $67 |
| July 15th 2025 | Goldman | Initiation | Buy | $65 |
| July 16th 2024 | Needham | Reiterated | Buy | $62← $46 |
| July 12th 2024 | Barclays | Initiation | Overweight | $52 |
| July 8th 2024 | Jefferies | Initiation | Buy | $63 |
| April 12th 2024 | Needham | Reiterated | Buy | $46← $36 |
| April 10th 2024 | Raymond James | Upgrade | Strong Buy | $48← $36 |
| March 11th 2024 | Piper Sandler | Initiation | Overweight | $43 |
Earnings History & Surprises
RVMDBeat Rate
33%
Last 18 quarters
Avg Surprise
-5.3%
EPS vs Estimate
Beats / Misses
6/11
1 met exactly
Latest EPS
$-1.61
Q4 2025
EPS Surprise History
Q1 24
-32.6%
$-1.14vs$-0.86
Q2 24
+6.2%
$-0.70vs$-0.75
Q3 24
-5.2%
$-0.81vs$-0.77
Q4 24
-5.2%
$-0.94vs$-0.89
Q1 25
-10.9%
$-1.12vs$-1.01
Q2 25
-0.9%
$-1.13vs$-1.12
Q3 25
-39.4%
$-1.31vs$-0.94
Q4 25
-13.4%
$-1.61vs$-1.42
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2026 | May 5, 2026 | — | — | — | — |
Q1 2026 | Feb 25, 2026 | $-1.60 | — | — | — |
Q4 2025 | Nov 5, 2025 | $-1.42 | $-1.61 | -13.4% | ✗ MISS |
Q3 2025 | Aug 6, 2025 | $-0.94 | $-1.31 | -39.4% | ✗ MISS |
Q2 2025 | May 7, 2025 | $-1.12 | $-1.13 | -0.9% | ✗ MISS |
Q1 2025 | Feb 26, 2025 | $-1.01 | $-1.12 | -10.9% | ✗ MISS |
Q4 2024 | Nov 6, 2024 | $-0.89 | $-0.94 | -5.2% | ✗ MISS |
Q3 2024 | Aug 7, 2024 | $-0.77 | $-0.81 | -5.2% | ✗ MISS |
Q2 2024 | May 8, 2024 | $-0.75 | $-0.70 | +6.2% | ✓ BEAT |
Q1 2024 | Feb 26, 2024 | $-0.86 | $-1.14 | -32.6% | ✗ MISS |
Q4 2023 | Nov 6, 2023 | $-1.01 | $-0.99 | +2.0% | ✓ BEAT |
Q3 2023 | Aug 8, 2023 | $-0.83 | $-0.92 | -10.8% | ✗ MISS |
Q2 2023 | May 8, 2023 | $-0.84 | $-0.72 | +14.3% | ✓ BEAT |
Q1 2023 | Feb 27, 2023 | $-0.84 | $-0.63 | +25.0% | ✓ BEAT |
Q4 2022 | Nov 7, 2022 | $-0.87 | $-0.87 | 0.0% | = MET |
Q3 2022 | Aug 9, 2022 | $-0.87 | $-0.82 | +5.7% | ✓ BEAT |
Q2 2022 | May 9, 2022 | $-0.82 | $-0.78 | +4.9% | ✓ BEAT |
Q1 2022 | Feb 28, 2022 | $-0.65 | $-0.71 | -9.2% | ✗ MISS |
Q4 2021 | Nov 10, 2021 | $-0.62 | $-0.72 | -16.1% | ✗ MISS |
Q3 2021 | Aug 11, 2021 | $-0.55 | $-0.60 | -9.1% | ✗ MISS |
Latest News
Revolution Medicines Begins Patient Enrollment In Phase 3 RASolute 304 Trial For Daraxonrasib In Resectable Pancreatic Cancer
📈 PositiveBenzinga•Dec 18, 2025, 01:11 PM
Wolfe Research Initiates Coverage On Revolution Medicines with Outperform Rating, Announces Price Target of $75
📈 PositiveBenzinga•Nov 18, 2025, 04:44 PM
Wedbush Maintains Outperform on Revolution Medicines, Raises Price Target to $80
📈 PositiveBenzinga•Nov 6, 2025, 01:37 PM
Needham Maintains Buy on Revolution Medicines, Raises Price Target to $72
📈 PositiveBenzinga•Nov 6, 2025, 01:19 PM
HC Wainwright & Co. Maintains Buy on Revolution Medicines, Raises Price Target to $73
📈 PositiveBenzinga•Nov 6, 2025, 12:54 PM
Revolution Medicines shares are trading higher. The company reported Q3 financial results.
📈 PositiveBenzinga•Nov 6, 2025, 12:32 PM
Revolution Medicines Q3 EPS $(1.61) Misses $(1.38) Estimate
📉 NegativeBenzinga•Nov 5, 2025, 09:04 PM
RBC Capital Initiates Coverage On Revolution Medicines with Outperform Rating, Announces Price Target of $77
📈 PositiveBenzinga•Nov 3, 2025, 02:20 PM
Revolution Medicines shares are trading higher after the FDA granted Orphan Drug Designation for its RAS(ON) multi-selective inhibitor Daraxonrasib.
📈 PositiveBenzinga•Oct 27, 2025, 01:41 PM
Revolution Medicines' Announces FDA Orphan Drug Designation For RAS(ON) Multi-Selective Inhibitor Daraxonrasib
📈 PositiveBenzinga•Oct 27, 2025, 12:16 PM
Revolution Medicines Reports 42% Objective Response Rate For Elironrasib In Heavily Pretreated KRAS G12C NSCLC Patients; Co To Highlight Data At AACR-NCI-EORTC Symposium October 23-25, 2025
📈 PositiveBenzinga•Oct 22, 2025, 04:16 PM
Mizuho Initiates Coverage On Revolution Medicines with Outperform Rating, Announces Price Target of $90
📈 PositiveBenzinga•Oct 21, 2025, 12:47 PM
Raymond James Maintains Strong Buy on Revolution Medicines, Raises Price Target to $76
📈 PositiveBenzinga•Oct 17, 2025, 04:34 PM
Revolution Medicines shares are trading higher after the company announced that the FDA granted the company a non-transferrable voucher for daraxonrasib, the company's RAS(ON) multi-selective inhibitor, under the Commissioner's National Priority Voucher pilot program.
📈 PositiveBenzinga•Oct 17, 2025, 12:55 PM
Wedbush Reiterates Outperform on Revolution Medicines, Maintains $77 Price Target
📈 PositiveBenzinga•Oct 17, 2025, 12:26 PM
FDA Awards First-Ever National Priority Vouchers to Nine Sponsors
📈 PositiveBenzinga•Oct 16, 2025, 09:27 PM•Also: ,
Stifel Reinstates Buy on Revolution Medicines, Announces $85 Price Target
📈 PositiveBenzinga•Oct 16, 2025, 01:46 PM•Also:
Revolution Medicines shares are trading higher. The company announced key leadership changes including appointing Alan Sandler, M.D.
📈 PositiveBenzinga•Sep 29, 2025, 05:56 PM
Goldman Sachs Maintains Buy on Revolution Medicines, Raises Price Target to $73
📈 PositiveBenzinga•Sep 12, 2025, 05:07 PM
Raymond James Assumes Revolution Medicines at Strong Buy, Announces Price Target of $72
📈 PositiveBenzinga•Sep 12, 2025, 12:13 PM
Frequently Asked Questions about RVMD
What is RVMD's current stock price?
Revolution Medicines, Inc. (RVMD) is currently trading at $78.78 per share. The stock has moved +3.71% today.
What is the analyst price target for RVMD?
The average analyst price target for RVMD is $79.50, based on 1 analyst.
What sector is Revolution Medicines, Inc. in?
Revolution Medicines, Inc. operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the NASDAQ exchange.
What is RVMD's market cap?
Revolution Medicines, Inc. has a market capitalization of $15.23 billion, making it a large-cap company.
Does RVMD pay dividends?
No, Revolution Medicines, Inc. does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorASND
Ascendis Pharma A/S
$199.99
Mkt Cap: $12.1B
BBIO
BridgeBio Pharma, Inc.
$76.30
Mkt Cap: $14.5B
BMRN
BioMarin Pharmaceutical Inc.
$61.15
Mkt Cap: $11.7B
EXEL
Exelixis, Inc.
$44.30
Mkt Cap: $11.9B
IONS
Ionis Pharmaceuticals, Inc.
$79.57
Mkt Cap: $12.6B
MDGL
Madrigal Pharmaceuticals, Inc.
$591.02
Mkt Cap: $13.1B
MRNA
Moderna, Inc.
$33.80
Mkt Cap: $13.2B
RNA
Avidity Biosciences, Inc.
$72.34
Mkt Cap: $9.5B
ROIV
Roivant Sciences Ltd.
$22.41
Mkt Cap: $15.6B
SMMT
Summit Therapeutics Inc.
$17.82
Mkt Cap: $13.3B
Explore stocks similar to RVMD for comparison